The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1492
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
The full article is available to subscribers Subscriber Login   

The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.

STANDARD TREATMENT — Mild to moderate psoriasis is generally treated with a topical corticosteroid. Vitamin D3 analogs and the retinoid tazarotene (Tazorac) are topical alternatives. When used alone, calcipotriene is about as effective in treating psoriasis as a medium-potency steroid. The combination of calcipotriene and betamethasone is more effective and better tolerated than either component alone.1,2 Phototherapy and systemic therapy, including biologic agents, are options for patients with moderate to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
Article code: 1492c
 Electronic, downloadable article - $25